natgillin/translations-raw huggingface dataset:
4.7 Effects on ability to drive and use machines Ogivri may have a minor influence on the ability to drive and use machines (see section 4.8). 
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Zdravilo Ogivri ima lahko blag vpliv na sposobnost vožnje in upravljanje strojev (glejte poglavje 4.8).
Trastuzumab loading dose should be administered as a 90-minute intravenous infusion. 
Uvajalni odmerek trastuzumaba se daje kot 90-minutna intravenska infuzija.
These medicines (or any other anthracyclines) can damage heart muscle and increase the risk of heart problems with Ogivri. 
Ta zdravila (ali kateri koli antraciklin) lahko poškodujejo srčno mišico in zvečajo tveganje za nastanek težav s srcem ob uporabi zdravila Ogivri;
FP + H: Fluoropyrimidine/cisplatin + Trastuzumab FP: Fluoropyrimidine/cisplatin a Odds ratio 
FP + H: fluoropirimidin/cisplatin + trastuzumab FP: fluoropirimidin/cisplatin a Razmerje obetov
Trastuzumab 1 Year N = 1702*** 
Trastuzumab 1 leto n = 1702***
If you develop any signs of heart failure (inadequate pumping of blood by the heart), your heart function may be checked more frequently (every six to eight weeks), you may receive treatment for heart failure or you may have to stop Ogivri treatment. 
Če bodo pri vas nastopili kakršni koli znaki srčnega popuščanja (to je, da vaše srce ne črpa krvi v zadostni meri), bo zdravnik delovanje vašega srca preveril pogosteje (vsakih šest do osem tednov); lahko prejmete zdravila proti srčnemu popuščanju ali pa boste morda morali prenehati z zdravljenjem z zdravilom Ogivri.
What Ogivri is and what it is used for 
Kaj je zdravilo Ogivri in za kaj ga uporabljamo
Time to Disease Progression, Median months 
Čas do napredovanja bolezni, mediana mesecev
If the first dose is well tolerated the next doses may be given over 30 minutes (see section 2 under “Warnings and precautions”). 
Če boste začetni odmerek dobro prenašali, boste nadaljnje odmerke prejeli v 30 minutah (glejte poglavje 2, “Opozorila in previdnostni ukrepi”).
• if you have severe breathing problems at rest due to your cancer or if you need oxygen treatment. 
• imate hude težave z dihanjem v mirovanju zaradi raka ali če potrebujete zdravljenje s kisikom.
When Ogivri binds to HER2 it stops the growth of such cells and causes them to die. 
Ko se zdravilo Ogivri veže na HER2, zaustavi rast teh celic in povzroči njihovo smrt.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči, ali načrtujete zanositev, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden boste prejeli to zdravilo.
Women of childbearing potential should be advised to use effective contraception during treatment with trastuzumab and for 7 months after treatment has concluded (see section 5.2). 
Ženskam v rodni dobi je treba svetovati, naj med zdravljenjem s trastuzumabom ter še 7 mesecev po zaključku zdravljenja uporabljajo učinkovito kontracepcijo (glejte poglavje 5.2).
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreeed subsequent updates of the RMP. 
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
• Hypersensitivity to the active substance, murine proteins, or to any of the excipients listed in section 6.1. 
• Preobčutljivost na učinkovino, murine beljakovine ali katero koli pomožno snov, navedeno v poglavju 6.1.
The European Medicines Agency has waived the obligation to submit the results of studies with the reference medicinal product containing trastuzumab in all subsets of the paediatric population for breast and gastric cancer (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij z referenčnim zdravilom, ki vsebuje trastuzumab, za vse skupine pediatrične populacije pri raku dojk in raku želodca (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Table 6 Efficacy results from study BO16348 
Preglednica 6 Rezultati učinkovitosti študije BO16348
If diluted aseptically, it may be stored for 24 hours (do not store above 30°C). 
Če je redčenje potekalo aseptično, se lahko raztopino hrani do 24 ur (ne shranjujte pri temperaturi nad 30 °C).
Heart problems can sometimes occur during treatment and occasionally after treatment has stopped and can be serious. 
Včasih se lahko med zdravljenjem ali občasno tudi po končanem zdravljenju pojavijo težave s srcem, ki so lahko resne.
If an alternate route of administration is required, other trastuzumab products offering such an option should be used 
Če je potrebna drugačna pot uporabe, je treba uporabiti druga zdravila, ki vsebujejo trastuzumab in omogočajo to možnost.
Observation N = 1697*** 
Opazovanje n = 1697***
Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies, ATC code: L01XC03 
Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe, monoklonska protitelesa, oznaka ATC: L01XC03
Only patients with a large amount of HER2 will be treated with Ogivri. 
Le bolniki z velikim številom HER2 bodo zdravljeni z zdravilom Ogivri.
In this trial, 87 % of patients entered had disease that was IHC3+, and 95 % of patients entered had disease that was IHC3+ and/or FISH-positive. 
V tem preskušanju je 87 % vključenih bolnikov imelo bolezen, ki je bila IHC 3+, 95 % vključenih bolnikov pa je imelo bolezen, ki je bila IHC 3+ in/ali FISH-pozitivna.
In all patients cardiac function should be monitored during treatment (e.g. every 12 weeks). 
Med zdravljenjem je treba nadzorovati delovanje srca pri vseh bolnikih (npr. vsakih 12 tednov).
21 (mg/mL, concentration of reconstituted solution) 
21 (mg/ml, koncentracija pripravljene raztopine)
Your doctor may prescribe Ogivri for the treatment of breast and gastric cancer when: 
Vaš zdravnik vam lahko zdravilo Ogivri predpiše za zdravljenje raka dojk in raka želodca, če:
• You should use effective contraception during treatment with Ogivri and for at least 7 months after treatment has ended. 
• Med zdravljenjem z zdravilom Ogivri in vsaj še 7 mesecev po zaključku zdravljenja morate uporabljati učinkovito kontracepcijo.
The product is not intended to be stored after reconstitution and dilution unless this has taken place under controlled and validated aseptic conditions. 
Zdravila po rekonstituciji ali redčenju ni dovoljeno shranjevati, razen če sta rekonstitucija in redčenje potekala v kontroliranih in validiranih aseptičnih pogojih.
The rate was highest in patients who were administered trastuzumab concurrently with a taxane (2.0 %). 
Delež je bil najvišji pri bolnikih, ki so trastuzumab prejeli sočasno s taksanom (2,0 %).
Very rarely, patients with severe breathing difficulties before treatment have died when they were given Ogivri. 
Zelo redko je pri bolnikih, ki so imeli hude težave z dihanjem pred začetkom zdravljenja, pri uporabi zdravila Ogivri prišlo do smrtnih primerov;
An absolute benefit of 13 percentage points in favour of the trastuzumab arm was estimated in terms of 3-year event-free survival rate (65 % versus 52 %). 
Absolutna korist 13 odstotnih točk v prid skupini, ki je prejemala trastuzumab, je bila ocenjena v smislu 3-letnega preživetja brez bolezni (65 % proti 52 %).
The efficacy results from the BO16348 trial following 12 months* and 8 years** median follow-up are summarized in Table 6: 
Rezultati učinkovitosti študije BO16348 po medianem času spremljanja 12 mesecev* in 8 let** so povzeti v preglednici 6:
150 mg vial 
150-mg viala
Study M77001: Full analysis set (intent-to-treat), 24 months results 
3 Študija M77001: celotna skupina bolnikov (bolniki, ki so jih nameravali zdraviti, intent-to-treat), rezultati po
Trastuzumab 1 Year N = 1693 
Trastuzumab 1 leto n = 1693
For intravenous use only after reconstitution and dilution 
Za intravensko uporabo le po rekonstituciji in razredčitvi.
AC→PH (vs. AC→P) (NSABP B-31 and NCCTG N9831)* 
AC→PH (v primerjavi z AC→P) (NSABP B-31 in NCCTG N9831)*
Treatment with Ogivri alone or with a taxane may affect the heart, especially if you have ever used an anthracycline (taxanes and anthracyclines are two other kinds of medicine used to treat cancer). 
Samostojno zdravljenje z zdravilom Ogivri ali v kombinaciji s taksanom lahko vpliva na srce, še posebno, če ste se kdaj zdravili z antraciklinom (taksani in antraciklini sta dve drugi vrsti zdravil, ki se uporabljata za zdravljenje raka).
Switching treatment between trastuzumab intravenous and trastuzumab subcutaneous formulation and vice versa. 
Prehod z zdravljenja s trastuzumabom v intravenski obliki na subkutano obliko in obratno
*Cmin,ss - Cmin at steady state **Cmax,ss = Cmax at steady state *** time to 90% of steady-state 
* Cmin, ss - Cmin v stanju dinamičnega ravnovesja ** Cmax, ss = Cmax v stanju dinamičnega ravnovesja *** čas do 90 % stanja dinamičnega ravnovesja
Patients were either naïve to trastuzumab intravenous treatment (20.3 %) or pre-exposed to trastuzumab intravenous (79.7 %). 
Bolniki še niso prejemali trastuzumaba v intravenski obliki (20,3 %) ali pa so bili predhodno izpostavljeni trastuzumabu v intravenski obliki (79,7 %).
In the neoadjuvant-adjuvant EBC study (BO22227), at a median follow-up exceeding 70 months, 10.1 % (30/296) of patients treated with trastuzumab intravenous developed antibodies against trastuzumab. 
V študiji neoadjuvantnega-adjuvantnega zgodnjega raka dojk (BO22227) z mediano spremljanja, ki je presegla 70 mesecev, so se pri 10,1 % bolnikov (30/296), zdravljenih z intravensko obliko trastuzumaba, razvila protitelesa proti trastuzumabu.
The non-linear elimination parameter values were 8.81 mg/day for the maximum elimination rate (Vmax) and 8.92 mcg/mL for the Michaelis-Menten constant (Km) for the MBC, EBC, and AGC patients. 
Vrednosti parametrov nelinearnega izločanja so bile 8,81 mg/dan za največjo hitrost izločanja (Vmax) in 8,92 µg/ml za Michaelis-Mentenovo konstanto (Km) za bolnike z MBC, EBC in AGC.
- The active substance is trastuzumab. 
- Učinkovina je trastuzumab.
Should an infusion reaction occur the infusion should be discontinued or the rate of infusion slowed and the patient should be monitored until resolution of all observed symptoms (see section 4.2). 
Če se pojavi infuzijska reakcija, je potrebno infundiranje zdravila Ogivri prekiniti ali upočasniti njegovo hitrost in bolnika nadzorovati, dokler vsi simptomi ne izzvenijo (glejte poglavje 4.2).
Any remaining reconstituted solution should be discarded. 
Ostanke rekonstituirane raztopine je treba zavreči.
For early breast cancer, metastatic breast cancer and metastatic gastric cancer, Ogivri is given every 3 weeks. 
Pri zgodnji obliki raka dojk, metastatskem raku dojk in metastatskem raku želodca se zdravilo Ogivri daje vsake 3 tedne.
L-histidine hydrochloride 
L-histidinijev klorid hidrat
• fluid retention (swelling) in the legs or arms, 
• zadrževanje tekočine (otekanje) v nogah ali rokah,
In patients who receive anthracycline-containing chemotherapy further monitoring is recommended, and should occur yearly up to 5 years from the last administration of trastuzumab, or longer if a continuous decrease of LVEF is observed. 
Pri bolnikih, ki prejemajo kemoterapijo z antraciklini, je priporočljivo nadaljnje spremljanje, ki ga je treba izvajati letno do 5 let po zadnjem dajanju trastuzumaba ali dlje, če iztisni delež levega prekata (LVEF) stalno pada.
After reconstitution with sterile water for injections, the reconstituted solution is physically and chemically stable for 48 hours at 2°C-8°C. 
Po rekonstituciji s sterilno vodo za injekcije je rekonstituirana raztopina fizikalno in kemijsko stabilna 48 ur pri temperaturi od 2 °C-8 °C.
Glucose solutions must not be used for dilution since these cause aggregation of the protein. 
Za redčenje ne uporabljajte raztopin glukoze, ker le-te povzročajo agregacijo beljakovin.
Paediatric population There is no relevant use of trastuzumab in the paediatric population. 
Pediatrična populacija Trastuzamab ni namenjen za uporabo pri pediatrični populaciji.
Other side effects can occur at any time during treatment with Ogivri, not just related to an infusion. 
Drugi neželeni učinki se lahko pojavijo kadar koli med zdravljenjem z zdravilom Ogivri in niso povezani le z infuzijo.
If you stop using Ogivri 
Če ste prenehali uporabljati zdravilo Ogivri
6.6 Special precautions for disposal and other handling Ogivri should be carefully handled during reconstitution. 
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Med rekonstitucijo se mora z zdravilom Ogivri pazljivo ravnati.
If you receive Ogivri with any other medicine to treat cancer, such as paclitaxel, docetaxel, an aromatase inhibitor, capecitabine, 5-fluorouracil, or cisplatin you should also read the patient information leaflets for these products. 
Če prejemate zdravilo Ogivri z drugimi zdravili za zdravljenje raka, kot so paklitaksel, docetaksel, zaviralec aromataze, kapecitabin, 5-fluorouracil ali cisplatin, preberite tudi navodila za uporabo teh zdravil.
Detailed information is available on the website of the European Medicines Agency http://www.ema.europa.eu. 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
Ogivri is a biosimilar medicinal product. 
Zdravilo Ogivri je podobno biološko zdravilo.
You must tell your doctor before receiving this medicine if you have HFI or if you can no longer take sweet foods or drinks because you feel sick, vomit or get unpleasant effects such as bloating, stomach cramps or diarrhoea. 
Preden prejmete to zdravilo, morate zdravnika obvestiti o svoji intoleranci za fruktozo, prav tako mu morate povedati, če ne morete več uživati sladke hrane ali sladkih napitkov, ker vam je slabo, bruhate ali se neprijetno počutite (npr. napenjanje, krči v trebuhu, driska).
Sorbitol content 
Vsebnost sorbitola
420 mg vial 
420-mg viala
Patients treated with trastuzumab are at increased risk for developing CHF (New York Heart Association [NYHA] Class II-IV) or asymptomatic cardiac dysfunction. 
Pri bolnikih, ki so se zdravili s trastuzumabom, obstaja večje tveganje za pojav kongestivnega srčnega popuščanja (New York Heart Association - NYHA, razred II−IV) ali asimptomatične motnje v delovanju srca.
Always keep this medicine in the closed original pack at a temperature of 2ºC - 8 ºC in a refrigerator. 
Zdravilo shranjujte v dobro zaprti originalni ovojnini pri temperaturi 2 °C - 8 °C, v hladilniku.
Experience of concurrent administration of trastuzumab with low dose anthracycline regimens is currently limited to the trial MO16432. 
Izkušnje z dajanjem trastuzumaba sočasno s shemami, ki vsebujejo majhne odmerke antraciklinov, so trenutno vezane na študijo MO16432.
Time to steadystate*** (week) 
Čas do stanja dinamične ga ravnovesja *** (tedni)
Study H0649g: IHC3+ patient subset 
1 Študija H0649g: IHC 3+ podskupina bolnikov
For the other parameters the improvements seen for the combination were for overall response (16.5 % versus 6.7 %); clinical benefit rate (42.7 % versus 27.9 %); time to progression (4.8 months versus 2.4 months). 
Pri drugih parametrih so bila izboljšanja pri kombinaciji vidna pri celokupnem odgovoru (16,5 % v primerjavi s 6,7 %), deležu klinične koristi (42,7 % v primerjavi s 27,9 %) in času do napredovanja bolezni (4,8 meseca v primerjavi z 2,4 meseca).
Study JP19959 was a sub study of BO18255 (ToGA) performed in male and female Japanese patients with advanced gastric cancer (AGC) to study the pharmacokinetics of capecitabine and cisplatin when used with or without trastuzumab. 
Študija JP19959 je bila podštudija BO18255 (ToGA) pri japonskih bolnikih in bolnicah z napredovalim rakom želodca (AGC - advanced gastric cancer), v kateri so proučevali farmakokinetiko kapecitabina in cisplatina s trastuzumabom ali brez njega.
Ogivri is for single-use only, as the product contains no preservatives. 
Zdravilo Ogivri je namenjeno samo za enkratno uporabo, saj ne vsebuje konzervansov.
The highest rate of cardiac dysfunction was seen in patients receiving trastuzumab concurrently with anthracycline/cyclophosphamide (27 %), and was significantly higher than for anthracycline/cyclophosphamide alone (7 % - 10 %). 
Najvišji delež motenj v delovanju srca je bil pri bolnikih, ki so trastuzumab prejemali sočasno z antraciklinom/ciklofosfamidom (27 %), bil je signifikantno višji kot pri jemanju samega antraciklina/ciklofosfamida (7 do 10 %).
MARKETING AUTHORISATION NUMBER(S) EU/1/18/1341/001 
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET Z ZDRAVILOM EU/1/18/1341/001 EU/1/18/1341/002
The frequency of progression in the liver was significantly reduced in patients treated with the combination of trastuzumab and paclitaxel, compared to paclitaxel alone (21.8 % versus 45.7 %; p = 0.004). 
Pogostnost napredovanja v jetrih je bila signifikantno zmanjšana pri bolnikih, zdravljenih s kombinacijo trastuzumaba in paklitaksela, v primerjavi s samim paklitakselom (21,8 % v primerjavi s 45,7 %; p = 0,004).
A: doxorubicin; C: cyclophosphamide; P: paclitaxel; H: trastuzumab * At median duration of follow up of 1.8 years for the patients in the AC→P arm and 2.0 years for patients in the AC→PH arm ** p value for OS did not cross the pre-specified statistical boundary for comparison of AC→PH vs. AC→P 
A: doksorubicin; C: ciklofosfamid; P: paklitaksel; H: trastuzumab; IZ: interval zaupanja * Po mediani spremljanja 1,8 leta za bolnike v skupini AC → P in 2,0 leta za bolnike v skupini AC → PH. ** Vrednost p za celokupno preživetje ni presegla vnaprej določene statistične meje za primerjavo AC → PH
Study H0648g: IHC3+ patient subset 
2 Študija H0648g: IHC 3+ podskupina bolnikov
In patients receiving trastuzumab after completion of adjuvant chemotherapy, the risk of cardiac dysfunction was associated with a higher cumulative dose of anthracycline given prior to initiation of trastuzumab and a body mass index (BMI) > 25 kg/m2. 
Pri bolnikih, ki so prejemali trastuzumab po zaključku adjuvantne kemoterapije, je bilo tveganje za pojav motnje v delovanju srca povezano z višjim kumulativnim odmerkom antraciklina, ki so ga dajali pred uvedbo trastuzumaba in visokim indeksom telesne mase (body mass index - BMI) > 25 kg/m².
Trastuzumab plus docetaxel4 N = 110 
Trastuzumab plus docetaksel4 n = 110
At the time of the analysis a total of 349 randomised patients had died: 182 patients (62.8 %) in the control arm and 167 patients (56.8 %) in the treatment arm. 
Do časa analize je umrlo skupaj 349 randomiziranih bolnikov: 182 bolnikov (62,8 %) v kontrolni skupini in 167 bolnikov (56,8 %) v skupini, ki je prejemala tudi zdravilo Ogivri.
• if you are allergic to trastuzumab, murine (mouse) proteins, or any of the other ingredients of this medicine (listed in section 6). 
• ste alergični na trastuzumab, murine (mišje) beljakovine ali katero koli sestavino tega zdravila
If you experience any of the above symptoms when your treatment with Ogivri has finished, you should see your doctor and tell them that you have previously been treated with Ogivri. 
Če se kateri koli izmed zgornjih simptomov pojavi po končanem zdravljenju z zdravilom Ogivri, obiščite zdravnika in ga obvestite o tem, da ste se zdravili z zdravilom Ogivri.
MBC and EBC patients had similar PK parameters (e.g. clearance (CL), the central compartment volume (Vc)) and population-predicted steady-state exposures (Cmin, Cmax and AUC). 
Bolniki z MBC in EBC so imeli podobne farmakokinetične parametre (npr. očistek, volumen centralnega prostora (Vc)) in izpostavljenosti v stanju dinamičnega ravnovesja (Cmin, Cmax in AUC).
Congestive heart failure (NYHA Class II - IV) is a common adverse reaction associated with the use of trastuzumab and has been associated with a fatal outcome (see section 4.4). 
Kongestivno srčno popuščanje, NYHA razred II-IV, je pogost neželeni učinek, povezan z uporabo trastuzumaba; povezan je bil tudi s smrtnim izidom (glejte poglavje 4.4).
or - intravenous 5-fluorouracil - 800 mg/m2/day as a continuous intravenous infusion over 5 days, 
ali - 5-fluorouracil intravensko - 800 mg/m²/dan v obliki kontinuirane intravenske infuzije 5 dni,
In 3 pivotal clinical trials of adjuvant trastuzumab given in combination with chemotherapy, the incidence of grade 3/4 cardiac dysfunction (specifically symptomatic Congestive Heart Failure) was similar in patients who were administered chemotherapy alone (i.e. did not receive trastuzumab) and in patients who were administered trastuzumab sequentially after a taxane (0.3-0.4 %). 
V treh ključnih kliničnih preskušanjih pri adjuvantnem zdravljenju s trastuzumabom v kombinaciji s kemoterapijo je bila incidenca motenj v delovanju srca stopnje 3/4 (še posebno simptomatskega kongestivnega srčnega popuščanja) podobna pri bolnikih, ki so prejeli le kemoterapijo (to je, da niso prejeli trastuzumaba), in pri bolnikih, ki so prejeli trastuzumab zaporedno po taksanu (0,3 do 0,4 %).
No incompatibilities between Ogivri and polyvinylchloride, polyethylene or polypropylene bags have been observed. 
Med zdravilom Ogivri in polivinilkloridnimi, polietilenskimi ali polipropilenskimi vrečkami inkompatibilnosti niso opazili.
Patients who had previously received anthracycline-based adjuvant chemotherapy were treated with paclitaxel (175 mg/m2 infused over 3 hours) with or without trastuzumab. 
Bolnike, ki so predhodno prejemali adjuvantno kemoterapijo na osnovi antraciklinov, so zdravili s paklitakselom (175 mg/m², infundirano v 3 urah) samim ali skupaj s trastuzumabom.
Patients with hereditary fructose intolerance (HFI) must not be given this medicine unless strictly necessary. 
Bolniki z dedno intoleranco na fruktozo tega zdravila ne smejo jemati, razen če je to nujno potrebno.
Observation N = 1693 
Opazovanje n = 1693
Docetaxel3 N = 94 
Docetaksel3 n = 94
*Co-primary endpoint of DFS of 1 year versus observation met the pre-defined statistical boundary **Final analysis (including crossover of 52 % of patients from the observation arm to trastuzumab) *** There is a discrepancy in the overall sample size due to a small number of patients who were randomised after the cut-off date for the 12-month median follow-up analysis 
** Končna analiza (vključno s prehodom 52 % bolnikov z opazovanja na trastuzumab) *** V celokupni velikosti vzorca je neskladje zaradi majhnega števila bolnikov, ki so jih randomizirali po preteku datuma, do katerega so upoštevali podatke za analizo po mediano 12-mesečnem spremljanju.
During an Ogivri infusion, chills, fever and other flu like symptoms may occur. 
Med infuzijo zdravila Ogivri se lahko pojavijo mrzlica, zvišana telesna temperatura in drugi simptomi, podobni gripi.
In order to prevent medication errors it is important to check the vial labels to ensure that the medicine being prepared and given is Ogivri (trastuzumab) and not trastuzumab emtansine. 
Za preprečitev napak pri dajanju zdravila je pomembno preveriti nalepke na vialah in tako zagotoviti, da je pripravljeno in uporabljeno zdravilo Ogivri (trastuzumab) in ne trastuzumab emtanzin.
Blood pressure increased 
1zvišanje krvnega tlaka
In order to prevent medication errors it is important to check the vial labels to ensure that the medicinal product being prepared and administered is trastuzumab and not trastuzumab emtansine. 
Za preprečitev napak pri dajanju zdravila je pomembno preveriti nalepke na vialah in tako zagotoviti, da je pripravljeno in uporabljeno zdravilo trastuzumab in ne trastuzumab emtanzin.
Other medicines and Ogivri 
Druga zdravila in zdravilo Ogivri
L-histidine hydrochloride, L-histidine, sorbitol, macrogol 3350, hydrochloric acid and sodium hydroxide. 
L-histidinijev klorid hidrat, L-histidin, sorbitol, makrogol 3350, klorovodikova kislina in natrijev hidroksid.